ISPOR 2022
Did you see our workshops and poster presentations at this year's ISPOR conference in Washington, DC?
PRECISIONheor Study Leads to New Legislation
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
The Power of Partnering to Support Healthcare Innovation and Improve Human Health
As the US healthcare system has shifted in recent years from a “volume-to-value” framework, there is increasing pressure on the industry to demonstrate the value of innovative therapies early in development, particularly those for diseases that present a large societal burden or for which there remains significant unmet need. The urgency to innovate underscores the importance of strategic partnering: cross-industry collaborations to support evidence generation that will, in turn, advance medical care and health outcomes.
Insights90: Jacki Chou
Have you heard about ICER’s new research protocol for assessing price increases of prescription drugs in California? PRECISIONheor’s Jacki Chou kicks off our new Insights90 series by breaking down this new protocol.
Featured Expert: Patrick Sullivan
This month, PRECISIONheor highlights Vice President Patrick Sullivan, PhD.
